“2020 will be remembered as the year of the biotech sector,” declares the author of today’s article, who proceeds to highlight two biotech stocks that Morgan Stanley is bullish on – and which have also earned “Strong Buy” consensus ratings from the analyst community at large. For these two biotech stocks with significant upside potential, CLICK HERE.
Morgan Stanley’s chief US equity strategist believes that stocks hit their true bottom on March 23rd – and that the current rally could well lead to a true recovery. To prepare for the next bull run, he’s advising clients to buy into small-cap stocks, so today’s article highlights “three micro-cap penny stock companies with super-low entry costs (a dollar per…
“With powerful demographic forces keeping interest rates lower for longer, investors (and financial advisors!) need to adjust their thinking for the future,” declares the author of today’s article, who cites a report from Morgan Stanley warning that, over the next 10 years, returns from a traditional 60/40 portfolio will be close to a century low. So what can investors do…